细胞减灭术加腹腔热灌注化疗治疗结直肠癌腹膜转移癌病例对照研究

被引：17

作者：

黄超群

周云峰

谢丛华

杨肖军

程伏林

熊斌

杨国樑

李雁

机构：

[1] 武汉大学中南医院肿瘤科,湖北省肿瘤医学临床研究中心,肿瘤生物学行为湖北省重点实验室

来源：

中国肿瘤临床 | 2013年 / 16期

基金：

中央高校基本科研业务费专项资金资助;

关键词：

结直肠癌; 细胞减灭术; 腹腔热灌注化疗; 腹膜癌;

D O I：

暂无

中图分类号：

R735.3 [肠肿瘤];

学科分类号：

100112 [医学生物化学与分子生物学];

摘要：

目的:分析细胞减灭术(CRS)加术中腹腔热灌注化疗术(HIPEC)对结直肠癌腹膜转移癌的疗效及安全性。方法:课题设计为回顾性病例对照研究,收集结直肠癌腹膜转移癌(CRC PC)患者资料,按临床病理参数匹配原则,分为CRS组(CRS+术后全身化疗)29例,HIPEC组(CRS+HIPEC+术后全身化疗)33例。分析两组的总体生存期(OS)及严重不良事件(SAE)。结果:两组患者临床病理学特征均衡可比,术中PCI评分及器官/腹膜切除情况相似。两组中位随访时间分别为41.9个月(6.5～110.0个月)和32.0个月(10.5～95.9个月),OS分别为8.5个月(95%CI:4.9～12.1个月)和14.5个月(95%CI:11.9～17.1月)(P=0.007)。术后30天内CRS组3例发生SAE,HIPEC组9例(P=0.126)。多因素分析显示,HIPEC、CC 0～1分、术后化疗周期≥6个周期为改善生存的独立预后因素。结论:CRS+HIPEC可改善CRCPC患者生存期,SAE无显著增加,安全性可接受。

引用

页码：979 / 983

页数：5

共 15 条

[1]

腹膜癌研究之我见 [J].

李雁 .

中国肿瘤临床, 2012, 39 (22) :1685-1686

[2]

肿瘤细胞减灭术联合腹腔热灌注化疗治疗结直肠癌腹膜转移癌 [J].

崔书中 ;

王佳泓 ;

张相良 .

中国肿瘤临床, 2012, (22) :1691-1695

[3]

Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis[J] Hassan Alaa Hammed al-Shammaa;Yutaka Yonemura; World Journal of Gastroenterology 2008,

[4]

Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model[J] Y. L. B.Klaver;T.Hendriks;R. M. L. M.Lomme;H. J. T.Rutten;R. P.Bleichrodt;I. H. J. T.de Hingh Br J Surg 2010,

[5]

Critical Assessment of Risk Factors for Complications After Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei[J] Akshat Saxena;Tristan D. Yan;Terence C. Chua;David L. Morris Annals of Surgical Oncology 2010,

[6]

Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?: A Systematic Review of Morbidity and Mortality[J] Terence C. Chua;Tristan D. Yan;Akshat Saxena;David L. Morris Annals of Surgery 2009,

[7]

A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin[J] Christopher Cao;Tristan D. Yan;Deborah Black;David L. Morris Annals of Surgical Oncology 2009,

[8]

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement[J] J. Esquivel;R. Sticca;P. Sugarbaker;E. Levine;T. D. Yan;R. Alexander;D. Baratti;D. Bartlett;R. Barone;P. Barrios;S. Bieligk;P. Bretcha-Boix;C. K. Chang;F. Chu;Q. Chu;S. Daniel;E. Bree;M. Deraco;L. Dominguez-Parra;D. Elias;R. Flynn;J. Foster;A. Garofalo;F. N. Gilly;O. Glehen;A. Gomez-Portilla;L. Gonzalez-Bayon;S. Gonzalez-Moreno;M. Go

[9]

Analysis of Prognostic Factors in Seventy Patients Having a Complete Cytoreduction plus Perioperative Intraperitoneal Chemotherapy for Carcinomatosis from Colorectal Cancer[J] Rodrigo Gomes da Silva;Paul H. Sugarbaker Journal of the American College of Surgeons 2006,

[10]

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival[J] T.D. Yan;F. Chu;M. Links;P.C. Kam;D. Glenn;D.L. Morris European Journal of Surgical Oncology 2006,

← 1 2 →